Sechenov First Moscow State Medical University (Sechenov University)

Самбурова, Н. В.; Жевак, Т. Н.; Литвицкий, Петр Францевич

doi:10.15690/vsp.v18i4.2042

Cited by 5 publications

(5 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В то же время, как показал сравнительный анализ, шансы на возникновение СЮ у пациентов мужского пола были статистически в 2,2 раза выше, нежели у девочек (р = 0,025). Полученные результаты соответствуют общемировым статистическим данным и свидетельствуют, вероятно, о нетривиальной роли гендерного фактора в предрасполагающих к возникновению СЮ процессах, при этом, как показывают многочисленные исследования, на агрессивность клинического течения опухоли при прочих равных условиях данный фактор существенного влияния не оказывает [1,4,5].…”

Section: Discussionunclassified

“…Одной из наиболее часто встречающихся злокачественных неоплазм костей и мягких тканей является саркома Юинга (СЮ). Данная опухоль составляет 10-15 % всех первичных злокачественных опухолей костной ткани и является 2-й по частоте встречаемости после остеогенной саркомы [1][2][3].…”

Section: Introductionunclassified

See 1 more Smart Citation

The experience of managing children and adolescents with Ewing’s sarcoma in the Pediatric Oncology Department of the Federal State Budgetary Institution “National Medical Research Center of Oncology”, Ministry of Health of Russia

Yurchenko

Kuznetsov

Kozel

et al. 2021

Ross. ž. det. gematol. onkol.

View full text Add to dashboard Cite

Relevance. One of the leading positions among malignant tumors of the musculoskeletal system in children and adolescents has recently begun to be occupied by Ewing’s sarcoma (ES). The prognosis of patients suffering from this onconosology remains extremely unfavorable even in the absence of distant metastases and timely initiation of antitumor treatment. The authors present 10 years of experience in the management of pediatric and adolescent patients with ES in the pediatric oncology department of the National Medical Research Center of Oncology, Ministry of Health of Russia.Materials and methods. The study included pediatric and adolescent patients diagnosed with ES of I—IV stages of various localizations, who were treated in the Pediatric Oncology Department of the National Medical Research Center of Oncology, Ministry of Health of Russia in the period from 2009 to 2019. We analyzed 2- and 5-year overall (OS) and event-free (EFS) survival in patients who received combined and complex antitumor treatment for various forms of tumor dissemination according to the EURO-EWING 2008protocol, which included neo-and adjuvant polychemotherapy, including high-dose, radical surgical treatment, and also radiation therapy.Results. The median 5-year OS and EFS in the general group of the studied formulations was 60 and 17 months, respectively. The indicators of 2- and 5-year OS and EFS in patients of the general group were 80.6 % and 56.7 %, 38.6 % and 10.6 %, respectively. The volume of the performed antitumor treatment, as well as the form of the advanced tumor process, did not have a significant effect on OS and EFS indicators (p > 0.05). At the same time, the chances of developing ES in boys were statistically significantly higher by 2.2 times in comparison with girls (95 % confidence interval 1.1—4.3).Conclusion. The obtained OS and EFS indices indicate unsatisfactory results of anticancer therapy and extremely high aggressiveness of the biological behavior of the tumor, regardless of the form of spread of the tumor process.

show abstract

Section: Discussionunclassified

Section: Introductionunclassified

The experience of managing children and adolescents with Ewing’s sarcoma in the Pediatric Oncology Department of the Federal State Budgetary Institution “National Medical Research Center of Oncology”, Ministry of Health of Russia

Yurchenko

Kuznetsov

Kozel

et al. 2021

Ross. ž. det. gematol. onkol.

View full text Add to dashboard Cite

show abstract

“…В настоящее время существует так называемое семейство саркомы Юинга, к которому относятся высокоагрессивные мезенхимальные опухоли с высокой частотой метастазирования в легкие и пиком заболеваемости в 15 лет [24][25][26][27]. Данные злокачественные новообразования происходят из нейроэктодермальных и/или мезенхимальных клеток.…”

Section: классификация опухолей костейunclassified

Expression of the immune checkpoint B7-H3 in tumor and its soluble form in serum of patients with bone neoplasms

Kushlinskii¹,

Ковалева²,

Alferov³

et al. 2021

Alʹm. klin. med.

View full text Add to dashboard Cite

B7-H3, also called CD276, is a type I transmembrane glycoprotein that is encoded on human chromosome 15. It was discovered back in 2001. The original study described it as a positive co-stimulant, as it can stimulate T-cell response and IFN-γ production. However, recent researches have shown that B7-H3 is involved in T-cell inhibition. A B7-H3 receptor has not been yet identified, and this may explain the complex immunomodulatory activity of B7-H3, as it can have more than one binding partner with different functions. Expression of the B7-H3 protein has been found on activated immune cells such as T-cells, NK cells and antigen presenting cells. Interestingly, it is overexpressed in a wide range of tumor cells and is associated with disease progression and outcome. The soluble form of this protein is also of particular interest. Increased sB7-H3 levels in the plasma of bone tumor patients might be their important diagnostic criterion.

show abstract

“…Согласно мировым статистическим данным, саркома Юинга (СЮ) занимает одну из лидирующих позиций среди злокачественной патологии опорно-двигательного аппарата у детей и подростков и 2-е место по частоте встречаемости после остеогенной саркомы [1]. СЮ -это основной представитель гетерогенной группы мелкосинеклеточных злокачественных опухолей -опухолей семейства СЮ [2].…”

Section: Introductionunclassified

“…К этиологическим факторам возникновения СЮ относят различного рода хромосомные аберрации с участием ключевого гена EWS и различных генов семейства транскрипционных факторов ETS-FLY, ERG, ETV1, ETV4, FEV и генов других семейств [1,5,6]. Результатом подобного рода слияний являются химерные онкопротеины, которые в свою очередь воздействуют на клетки-мишени-предшественники СЮ, вызывая их трансформацию и озлокачествление, тем самым запуская каскад реакций саркомогенеза.…”

Section: Introductionunclassified

ZEB1 as an additional predictor of tumor progression in Ewingʼs sarcoma. Results of a morphological study on a population of children and adolescents

Юрченко

Ulyanova

Бурцев

et al. 2020

Ross. ž. det. gematol. onkol.

View full text Add to dashboard Cite

Relevance. Ewingʼs sarcoma (ES) is a classic representative of the extensive family of ES tumors, which occupies one of the leading positions among the malignant pathology of the musculoskeletal system in children and adolescents. This group is characterized by an extremely large variety of morphological, immunohistochemical, and molecular genetic characters among its representatives. The absence of specific pathognomonic markers for ES, as well as the presence of wide variability of clinical manifestations complicates the differential diagnosis. Materials and methods. The study included patients of childhood and adolescence with a localized and generalized form of ES/PNEТ of various localizations undergoing treatment in the conditions of the Department of Pediatric Oncology of the Federal State Budgetary Research Center for Oncology from 2009 to 2019. As the material, the tissue of the primary tumor of ES/PNEТ from paraffin blocks was used, obtained from 67 patients during the primary biopsy, as well as after the surgical stage as part of a combined or complex treatment. The expression of ZEB1 was determined immunohistochemically.Results. The highest average level of expression of ZEB1 protein was observed in group 4 with a generalized form of ES (surgical material) and amounted to 60.8 ± 2.2 %, the minimum level was detected in group 2 with a localized form of ES (surgical material) and amounted to 29.2 ± 3.0 %. Between groups 2 (localized form) and 4 (generalized form) statistically significant differences were noted (p = 0.026).Conclusion. As a result of an immunohistochemical study, the ZEB1 protein showed its prognostic significance when comparing groups with a localized and generalized form of ES (p = 0.026). The predominance of the expression level of ZEB1 protein in the group with the generalized form statistically significantly increased the chances of metastasis by 3.6 times (95 % CI 1.13-11.8).

show abstract

Sechenov First Moscow State Medical University (Sechenov University)

Cited by 5 publications

References 43 publications

The experience of managing children and adolescents with Ewing’s sarcoma in the Pediatric Oncology Department of the Federal State Budgetary Institution “National Medical Research Center of Oncology”, Ministry of Health of Russia

The experience of managing children and adolescents with Ewing’s sarcoma in the Pediatric Oncology Department of the Federal State Budgetary Institution “National Medical Research Center of Oncology”, Ministry of Health of Russia

Expression of the immune checkpoint B7-H3 in tumor and its soluble form in serum of patients with bone neoplasms

ZEB1 as an additional predictor of tumor progression in Ewingʼs sarcoma. Results of a morphological study on a population of children and adolescents

Contact Info

Product

Resources

About